ADVERTISEMENT
ADVERTISEMENT

Tag: Exon

Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy

Media ReleaseCopenhagen, Denmark, October 15, 2021 Janssen-Cilag International NV (Janssen) received a positive CHMP opinion recommending conditional marketing authorization of amivantamab in Europe for the treatment of adult patients with ...

ADVERTISEMENT